Managed entry agreements for oncology drugs: Lessons from the European experience to inform the future

Frontiers in Pharmacology

Volumn 8, Issue APR, 2017, Pages

  Pauwels, Kim ^a   Huys, Isabelle ^a   Vogler, Sabine ^b   Casteels, Minne ^a   Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b GESUNDHEIT ÖSTERREICH GMBH   (Austria)

Author keywords

Cancer; Managed entry agreements; Reimbursement; Risk sharing

Indexed keywords

ARTICLE; BELGIUM; CZECH REPUBLIC; ENGLAND; FRANCE; HEALTH CARE POLICY; HUMAN; ITALY; MANAGED ENTRY AGREEMENT; MARKET; NETHERLANDS; ONCOLOGY; SCOTLAND; SEMI STRUCTURED INTERVIEW; SWEDEN; SYSTEMATIC REVIEW; WALES;

EID: 85018384674     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2017.00171     Document Type: Article

References (23)

1. Abboud, C., Berman, E., Cohen, A., Cortes, J., DeAngelo, D., Deininger, M., et al. (2013). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 121, 4439-4442. doi: 10.1182/blood-2013-03-490003
2. Carlson, J. J., Garrison, L. P., and Sullivan, S. D. (2009). Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals. J. Manag. Care Pharm. 15, 683-687. doi: 10.18553/jmcp.2009.15.8.683
3. Edlin, R., Hall, P., Wallner, K., and McCabe, C. (2014). Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies? Value Health 17, 438-444. doi: 10.1016/j.jval.2014.01.010
4. Eichler, H. G., Baird, L. G., Barker, R., BlØechl-Daum, B., Borlum-Kristensen, F., Brown, J., et al. (2015). From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin. Pharmacol. Ther. 97, 234-246. doi: 10.1002/cpt.59
5. Espin, J., Rovira, J., and Garcia, L. (2011). Experiences and Impact of European Risk-Sharing Schemes Focusing on Oncology Medicines. European Commission
6. Executive Insight Health Care Consultants (2016). Innovative Contracting: A Review
7. Ferrario, A., and Kanavos, P. (2015). Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc. Sci. Med. 124, 39-47. doi: 10.1016/j.socscimed.2014.11.003
8. Fojo, T., and Grady, C. (2009). How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl. Cancer Inst. 101, 1044-1048. doi: 10.1093/jnci/djp177
9. Fojo, T., and Lo, A. W. (2016). Price, value, and the cost of cancer drugs. Lancet Oncol. 17, 3-5. doi: 10.1016/S1470-2045(15)00564-1
10. Garattini, S., and Bertele, V. (2002). Efficacy, safety, and cost of new anticancer drugs. BMJ. 325, 269-271. doi: 10.1136/bmj.325.7358.269
11. Gozzo, L., Navarria, A., Drago, V., Longo, L., Mansueto, S., Pignataro, G., et al. (2016). Linking the price of cancer drug treatments to their clinical value. Clin. Drug Investig. 36, 579-589. doi: 10.1007/s40261-016-0403-1
12. Jönsson, B., Hofmarcher, T., Lindgren, P., and Wilking, N. (2016). The cost and burden of cancer in the European Union 1995-2014. Eur. J. Cancer 66, 162-170. doi: 10.1016/j.ejca.2016.06.022
13. Leopold, C., Vogler, S., Mantel-Teeuwisse, A. K., de Joncheere, K., Leufkens, H. G., and Laing, R. (2012). Differences in external price referencing in Europe: a descriptive overview. Health Policy 104, 50-60. doi: 10.1016/j.healthpol.2011.09.008
14. Mestre-Ferrandiz, J., Towse, A., Dellamano, R., and Pistolllato, M. (2015). Multi-Indication Pricing: Pros, Cons and Applicability to the UK
15. Morel, T., Arickx, F., Befrits, G., Siviero, P., van der Meijden, C., Xoxi, E., et al. (2013). Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet J. Rare Dis. 8:198. doi: 10.1186/1750-1172-8-198
16. Navarria, A., Drago, V., Gozzo, L., Longo, L., Mansueto, S., Pignataro, G., et al. (2015). Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure. Value Health. 18, 131-136. doi: 10.1016/j.jval.2014.09.007
17. Pauwels, K. (2016). Financial based agreements and performance based agreements: the Belgian experience. J. Pharm. Policy Practi. 8(Suppl 1): O1. doi: 10.1186/2052-3211-8-S1-O1
18. Pauwels, K., Huys, I., Casteels, M., De Nys, K., and Simoens, S. (2014). Market access of cancer drugs in European countries: improving resource allocation. Target. Oncol. 9, 95-110. doi: 10.1007/s11523-013-0301-x
19. Pauwels, K., Huys, I., Casteels, M., and Simoens, S. (2016). Industry perspectives on market access of innovative drugs: the relevance for oncology drugs. Front. Pharmacol. 7:144. doi: 10.3389/fphar.2016.00144
20. Toumi, M., Jaroslawski, S., Sawada, T., and Kornfeld, Å. (2017). The use of surrogate and patient-relevant endpoints in outcomes-based market access agreements: current debate. Appl. Health Econ. Health Policy 15, 5-11. doi: 10.1007/s40258-016-0274-x
21. van de Vooren, K., Curto, A., Freemantle, N., and Garattini, L. (2015). Market-access agreements for anti-cancer drugs. J. R. Soc. Med. 108, 166-170. doi: 10.1177/0141076814559626
22. Vogler, S., Vitry, A., and Babar, Z. U. (2015). Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol. 17, 39-47. doi: 10.1016/S1470-2045(15)00449-0
23. Vogler, S., Zimmermann, N., Habl, C., Piessnegger, J., and Bucsics, A. (2012). Discounts and rebates granted to public payers for medicines in European countries. South. Med. Rev. 5, 38-46